Literature DB >> 33660217

Targeting "undruggable" c-Myc protein by synthetic lethality.

Chen Wang1,2,3, Hui Fang2, Jiawei Zhang4, Ying Gu5,6,7.   

Abstract

Synthetic lethal screening, which exploits the combination of mutations that result in cell death, is a promising method for identifying novel drug targets. This method provides a new avenue for targeting "undruggable" proteins, such as c-Myc. Here, we revisit current methods used to target c-Myc and discuss the important functional nodes related to c-Myc in non-oncogene addicted network, whose inhibition may cause a catastrophe for tumor cell destiny but not for normal cells. We further discuss strategies to identify these functional nodes in the context of synthetic lethality. We review the progress and shortcomings of this research field and look forward to opportunities offered by synthetic lethal screening to treat tumors potently.

Entities:  

Keywords:  c-Myc; synthetic lethality; transcription factor; undruggable

Year:  2021        PMID: 33660217     DOI: 10.1007/s11684-020-0780-y

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  84 in total

1.  c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation.

Authors:  Anne Wilson; Mark J Murphy; Thordur Oskarsson; Konstantinos Kaloulis; Michael D Bettess; Gabriela M Oser; Anne-Catherine Pasche; Christian Knabenhans; H Robson Macdonald; Andreas Trumpp
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

2.  The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc.

Authors:  Xiao-Xin Sun; Xia He; Li Yin; Masayuki Komada; Rosalie C Sears; Mu-Shui Dai
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-09       Impact factor: 11.205

3.  Genetics of natural populations; experimental reproduction of some of the changes caused by natural selection in certain populations of Drosophila pseudoobscura.

Authors:  S WRIGHT; T DOBZHANSKY
Journal:  Genetics       Date:  1946-03       Impact factor: 4.562

4.  Functional genomics identifies therapeutic targets for MYC-driven cancer.

Authors:  Masafumi Toyoshima; Heather L Howie; Maki Imakura; Ryan M Walsh; James E Annis; Aaron N Chang; Jason Frazier; B Nelson Chau; Andrey Loboda; Peter S Linsley; Michele A Cleary; Julie R Park; Carla Grandori
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

5.  Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster.

Authors:  J C Lucchesi
Journal:  Genetics       Date:  1968-05       Impact factor: 4.562

6.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.

Authors:  Catherine M Shachaf; Andrew M Kopelman; Constadina Arvanitis; Asa Karlsson; Shelly Beer; Stefanie Mandl; Michael H Bachmann; Alexander D Borowsky; Boris Ruebner; Robert D Cardiff; Qiwei Yang; J Michael Bishop; Christopher H Contag; Dean W Felsher
Journal:  Nature       Date:  2004-10-10       Impact factor: 49.962

7.  c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression.

Authors:  Troy A Baudino; Catriona McKay; Helene Pendeville-Samain; Jonas A Nilsson; Kirsteen H Maclean; Elsie L White; Ann C Davis; James N Ihle; John L Cleveland
Journal:  Genes Dev       Date:  2002-10-01       Impact factor: 11.361

8.  Non-transcriptional control of DNA replication by c-Myc.

Authors:  David Dominguez-Sola; Carol Y Ying; Carla Grandori; Luca Ruggiero; Brenden Chen; Muyang Li; Denise A Galloway; Wei Gu; Jean Gautier; Riccardo Dalla-Favera
Journal:  Nature       Date:  2007-06-27       Impact factor: 49.962

9.  USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer.

Authors:  J Pan; Q Deng; C Jiang; X Wang; T Niu; H Li; T Chen; J Jin; W Pan; X Cai; X Yang; M Lu; J Xiao; P Wang
Journal:  Oncogene       Date:  2014-10-06       Impact factor: 9.867

Review 10.  Strategies to Inhibit Myc and Their Clinical Applicability.

Authors:  Jonathan R Whitfield; Marie-Eve Beaulieu; Laura Soucek
Journal:  Front Cell Dev Biol       Date:  2017-02-23
View more
  5 in total

Review 1.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 2.  Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response.

Authors:  Mateusz Kciuk; Adrianna Gielecińska; Somdutt Mujwar; Mariusz Mojzych; Renata Kontek
Journal:  Int J Mol Sci       Date:  2022-03-24       Impact factor: 5.923

3.  Target c-Myc to treat pancreatic cancer.

Authors:  Moein Ala
Journal:  Cancer Biol Ther       Date:  2022-01-03       Impact factor: 4.742

Review 4.  The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer.

Authors:  Eleazer P Resurreccion; Ka-Wing Fong
Journal:  Metabolites       Date:  2022-05-27

Review 5.  Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs.

Authors:  Damiano Bartolucci; Andrea Pession; Patrizia Hrelia; Roberto Tonelli
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.